Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 134 Published: March 31, 2022 Report Code: GMDGDHC22027TDB

Tyrosine Protein Kinase JAK3 pipeline market research report provides comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

Key MoA in the Tyrosine Protein Kinase JAK3 Pipeline Market

The key MoA in the Tyrosine Protein Kinase JAK3 pipeline market is Tyrosine Protein Kinase JAK3 Inhibitor.

Key RoA in the Tyrosine Protein Kinase JAK3 Pipeline Market

The key RoA in the Tyrosine Protein Kinase JAK3 pipeline market are oral, topical, ophthalmic, cutaneous, and inhalational. Oral has the highest pipeline market.

Tyrosine Protein Kinase JAK3 Pipeline Market, by RoA

Tyrosine Protein Kinase JAK3 Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Type in the Tyrosine Protein Kinase JAK3 Pipeline Market

The key molecule type in the Tyrosine Protein Kinase JAK3 pipeline market is small molecule.

Key Companies in the Tyrosine Protein Kinase JAK3 Pipeline Market

The key companies in the Tyrosine Protein Kinase JAK3 pipeline market are Aclaris Therapeutics Inc, Alexion Pharmaceuticals Inc, Arrien Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Celon Pharma SA, Clevexel Pharma SA, and Daewoong Pharmaceutical Co Ltd. Aclaris Therapeutics Inc has the highest pipeline products.

Tyrosine Protein Kinase JAK3 Pipeline Market, by Companies

Tyrosine Protein Kinase JAK3 Pipeline Market, by Companies

To know about more companies, download a free report sample

Market report overview

Key MoA Tyrosine Protein Kinase JAK3 Inhibitor
Key RoA Oral, Topical, Ophthalmic, Cutaneous, and Inhalational
Key molecule type Small Molecule
Key companies Aclaris Therapeutics Inc, Alexion Pharmaceuticals Inc, Arrien Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Celon Pharma SA, Clevexel Pharma SA, and Daewoong Pharmaceutical Co Ltd

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Players

Aclaris Therapeutics Inc

Alexion Pharmaceuticals Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Bristol-Myers Squibb Co

Celon Pharma SA

Clevexel Pharma SA

Daewoong Pharmaceutical Co Ltd

Guangdong Zhongsheng Pharmaceutical Co Ltd

Impetis Biosciences Ltd

Japan Tobacco Inc

KBP Biosciences Co Ltd

Kinaset Therapeutics Inc

MedAvail Holdings Inc

Merck & Co Inc

Oncostellae SL

Pfizer Inc

Shenzhen Chipscreen Biosciences Co Ltd

Simcere Pharmaceutical Group Ltd

Theravance Biopharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK3 – Overview

Tyrosine Protein Kinase JAK3 – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase JAK3 – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK3 – Companies Involved in Therapeutics Development

Tyrosine Protein Kinase JAK3 – Drug Profiles

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) – Dormant Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) – Discontinued Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Aclaris Therapeutics Inc, 2022

Pipeline by Alexion Pharmaceuticals Inc, 2022

Pipeline by Arrien Pharmaceuticals LLC, 2022

Pipeline by Astellas Pharma Inc, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Celon Pharma SA, 2022

Pipeline by Clevexel Pharma SA, 2022

Pipeline by Daewoong Pharmaceutical Co Ltd, 2022

Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2022

Pipeline by Impetis Biosciences Ltd, 2022

Pipeline by Japan Tobacco Inc, 2022

Pipeline by KBP Biosciences Co Ltd, 2022

Pipeline by Kinaset Therapeutics Inc, 2022

Pipeline by MedAvail Holdings Inc, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by Oncostellae SL, 2022

Pipeline by Pfizer Inc, 2022

Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022

Pipeline by Simcere Pharmaceutical Group Ltd, 2022

Pipeline by Theravance Biopharma Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Dormant Products, 2022 (Contd..3)

Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Frequently Asked Questions

Enquire Before Buying
$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.